Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03662542 · ClinicalTrials.gov registry record · Phase 2
A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
A Phase 2 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 214
- Enrollment target
NCT03662542 is a Phase 2 study that has completed, run by Janssen Research & Development. The registered enrollment target is 214 participants.
The verdict
NCT03662542, a Phase 2 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 214 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the clinical efficacy and safety of combination therapy with guselkumab and golimumab in participants with moderately to severely active ulcerative colitis (UC).
Interventions
- DRUG Placebo
- DRUG Guselkumab Dose 1
- DRUG Guselkumab Dose 2
- DRUG Golimumab Dose 1
- DRUG Golimumab Dose 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 214 participants |
| Start Date | 2018-11-20 |
| Est. Completion | 2021-11-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03662542
The ClinicalTrials.gov registry entry for NCT03662542 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 214 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT03662542 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03662542 about?
NCT03662542 is a clinical study titled "A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis". The purpose of this study is to evaluate the clinical efficacy and safety of combination therapy with guselkumab and golimumab in participants with moderately to severely active ulcerative colitis (UC).
What is the current status of trial NCT03662542?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 214 participants. The study started on 2018-11-20. Estimated completion is 2021-11-15.
What interventions are being tested in trial NCT03662542?
The interventions under investigation include: Placebo (DRUG), Guselkumab Dose 1 (DRUG), Guselkumab Dose 2 (DRUG), Golimumab Dose 1 (DRUG), Golimumab Dose 2 (DRUG).
Who is sponsoring clinical trial NCT03662542?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.